Insider Trading April 20, 2026 05:09 PM

Aehr Test Systems VP Sells $218,790 in Stock as Company Books Record Orders

Executive sale coincides with a $41 million hyperscaler production order and mixed quarterly results for Aehr Test Systems (AEHR)

By Ajmal Hussain AEHR
Aehr Test Systems VP Sells $218,790 in Stock as Company Books Record Orders
AEHR

Vernon Rogers, Executive Vice President of Sales & Marketing at Aehr Test Systems (NASDAQ: AEHR), sold 2,431 shares on April 20, 2026, for $90.00 per share, receiving $218,790. After the sale he directly holds 159,202 shares, including shares subject to unvested restricted stock units. The company also reported a record $41 million production order from a major hyperscale customer and posted mixed Q3 2026 financials: an EPS beat but a revenue miss, alongside record quarterly bookings and a backlog exceeding $50 million.

Key Points

  • Insider transaction: Vernon Rogers sold 2,431 shares at $90.00 each on April 20, 2026, totaling $218,790 and now directly holds 159,202 shares including unvested RSUs.
  • Commercial milestone: Aehr secured a record $41 million production order from a major hyperscale customer for package-level burn-in of custom AI processor ASICs, deliveries starting fiscal 2027.
  • Financial snapshot: Q3 2026 EPS beat (-$0.05 vs -$0.07) but revenue missed ($10.3M vs $10.8M); record bookings of $37.2M and backlog exceeding $50M.

Vernon Rogers, Aehr Test Systems' Executive Vice President of Sales & Marketing, disposed of 2,431 shares of common stock on April 20, 2026, at $90.00 per share, generating proceeds of $218,790. Following that transaction, Rogers is reported to directly own 159,202 shares of Aehr Test Systems common stock. The reported holding includes shares that remain subject to unvested restricted stock units.

The insider sale arrives amid notable commercial and financial developments for the Fremont, California-based test and burn-in equipment company. Aehr Test Systems disclosed a single production order valued at $41 million from a major hyperscale customer. The order, identified by the company as the largest in its history, covers package-level burn-in for custom AI processor ASICs and encompasses Sonoma high-power package-level test systems, burn-in modules, and device-specific sockets. According to the company, deliveries tied to that order are expected to commence in fiscal 2027.

Financial results for the company in the third quarter of fiscal 2026 were mixed. Aehr reported adjusted earnings per share of -$0.05, which outperformed the consensus estimate of -$0.07. Revenue for the quarter totaled $10.3 million, however, falling short of the expected $10.8 million. Despite the top-line shortfall, the company recorded record quarterly bookings totaling $37.2 million, and its effective backlog was reported as exceeding $50 million.

Analyst responses to these developments were varied. Freedom Broker raised its price target on Aehr Test Systems to $61 while maintaining a Hold rating. Lake Street increased its target to $56 and continued to rate the stock a Buy. Both firms referenced the company’s strong bookings momentum as a constructive indicator for future performance.

The transaction by Rogers and the company’s recent commercial milestones together present a snapshot of Aehr Test Systems during a period of active order flow and mixed near-term financial metrics. The sale reduced Rogers' immediate stake by the 2,431 shares transacted on April 20, 2026, while his remaining position continues to include unvested restricted stock units.


Summary

  • Vernon Rogers sold 2,431 Aehr Test Systems shares at $90.00 each on April 20, 2026, netting $218,790 and leaving him with 159,202 shares including unvested RSUs.
  • Aehr received a $41 million production order from a major hyperscale customer for package-level burn-in of custom AI processor ASICs, with deliveries beginning in fiscal 2027.
  • Q3 2026 results showed an EPS beat (-$0.05 vs -$0.07 forecast) but a revenue miss ($10.3 million vs $10.8 million forecast); bookings hit a record $37.2 million and backlog topped $50 million.

Risks

  • Revenue shortfall risk - The company reported revenue below expectations in Q3 2026, which may signal near-term top-line pressure for the semiconductor test equipment sector.
  • Timing risk - Deliveries for the $41 million production order are scheduled to begin in fiscal 2027, introducing execution and timing uncertainty for revenue recognition in the semiconductor and AI hardware markets.
  • Analyst divergence - Mixed analyst reactions and differing price targets indicate uncertainty in near-term valuation and sentiment within capital markets and investor coverage.

More from Insider Trading

OrbiMed Expands Stake in Traws Pharma via Strategic Private Placement Apr 28, 2026 Rexford Industrial Realty General Counsel Completes $1.18 Million Stock Sale Apr 28, 2026 Bicara Therapeutics CMO Executes Rule 10b5-1 Trading Plan Involving Share Sales and Option Exercises Apr 28, 2026 Abbott Laboratories Director Daniel Starks Executes Substantial Open Market Share Purchase Apr 28, 2026 BlackRock President Robert Kapito Executes $9.2 Million Share Sale Apr 28, 2026